Who has been buying GC Genome stock?

2 distinct insiders have filed 1 disclosed insider purchases in GC Genome (340450), most recently on 2026-01-23. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does GC Genome have?

GC Genome has 1 buy-side and 9 sell-side disclosures on record, covering ₩14.7B ($10.2M) in total reported value, spanning 2025-06-11 to 2026-01-23.

Where does StockDrifts get GC Genome insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

GC Genome 340450

Company

지씨지놈GC Genome

Insiders

Buys

Total Value

₩14.7B ($10.2M)

Avg Return

-1.97%

Last Filing

2026-01-23

GC Genome (340450) has 1 disclosed insider purchases and 9 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩14.7B ($10.2M) in reported transaction value. The earliest filing StockDrifts holds for GC Genome is dated 2025-06-11; the most recent is 2026-01-23. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -1.97%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-01-23	BUY	Market Buy	조은해 Eunhae Jo	Director of Research Institute	10.0K	₩7,330	+17.5%	₩73M ($51K)
2025-12-17	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-3.6K	₩6,770	-27.2%	₩25M ($17K)
2025-12-16	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-95.0K	₩7,200	-19.6%	₩684M ($475K)
2025-12-15	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-531.0K	₩7,850	-9.7%	₩4.2B ($2.9M)
2025-12-12	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-100.0K	₩7,980	-7.9%	₩798M ($554K)
2025-12-11	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-259.4K	₩7,890	-9.1%	₩2.0B ($1.4M)
2025-06-18	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-45.0K	₩9,500	+9.4%	₩428M ($297K)
2025-06-17	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-55.0K	₩9,300	+7.4%	₩512M ($355K)
2025-06-16	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-100.0K	₩9,280	+7.2%	₩928M ($644K)
2025-06-13	SELL	Market Sell	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	-511.1K	₩9,820	+12.3%	₩5.0B ($3.5M)
2025-06-11	BUY	신규상장	녹십자 green cross	-	4.6M	₩11,100	-22.4%	₩51.5B ($35.7M)
2025-06-11	BUY	신규상장	조은해 Eunhae Jo	Director of Research Institute	138.3K	₩11,100	-22.4%	₩1.5B ($1.1M)
2025-06-11	BUY	신규상장	기창석 Ki Chang-seok	CEO	169.3K	₩11,100	-22.4%	₩1.9B ($1.3M)
2025-06-11	BUY	신규상장	지노베이션1호사모투자 Innovation No. 1 private equity investment	-	3.6M	₩11,100	-22.4%	₩39.5B ($27.4M)

Frequently asked questions

Who has been buying GC Genome stock?: 2 distinct insiders have filed 1 disclosed insider purchases in GC Genome (340450), most recently on 2026-01-23. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does GC Genome have?: GC Genome has 1 buy-side and 9 sell-side disclosures on record, covering ₩14.7B ($10.2M) in total reported value, spanning 2025-06-11 to 2026-01-23.
Where does StockDrifts get GC Genome insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for GC Genome. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.